Leerink Partners Upgrades Solid Biosciences to Outperform, Maintains Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has upgraded Solid Biosciences (NASDAQ:SLDB) from Market Perform to Outperform, maintaining the price target at $12.
June 24, 2024 | 11:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Leerink Partners upgraded Solid Biosciences from Market Perform to Outperform, maintaining the price target at $12. This upgrade could positively influence investor sentiment and drive short-term stock price appreciation.
The upgrade from Market Perform to Outperform by a reputable analyst firm like Leerink Partners is likely to boost investor confidence. Maintaining the price target at $12 suggests that the firm sees continued potential in the stock, which could lead to short-term price gains.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100